COL1A1 and steatosis: In addition, we observed genotype-specific differences in response to drug treatment as resmetirom demonstrated greater efficacy in the PNPLA3 wild-type CC LAMPS than that in the GG variant in the reduction of steatosis, stellate cell activation, and the secretion of marker COL1A1 (Table 3).